Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca and its development ... with a history of asthma exacerbations and uncontrolled asthma receiving currently approved inhaled treatment versus placebo. The trial showed annual asthma ...

[1] All of these pathophysiologic features are largely represented in asthma, and therefore, anticholinergic drugs have been ... and research activities from: AstraZeneca, Boehringer Ingelheim ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) ...

AZD-8630 is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for 50% of the company’s total revenue by 2030.

2, 2025 — A new, non-invasive nasal swab test for kids that diagnoses specific asthma subtype, or endotype, could help clinicians prescribe medications more precisely and pave the way for ...

Therefore, treating asthma is a matter of managing it to ward off symptoms and prevent exacerbations (asthma attacks), typically with inhaled medications called controller inhalers, and relieving ...